-
公开(公告)号：US20120258047A1
公开(公告)日：2012-10-11
申请号：US13514745
申请日：2010-12-22
IPC分类号： A61K9/14 , A61K33/44 , A61K49/00 , C12P1/00 , A61K38/43 , A61K38/02 , C12N1/00 , A61K35/74 , A61K35/66 , B82Y5/00
CPC分类号： B01J13/22 , A23P10/30 , A61K9/5031 , A61K9/5073 , A61L2300/214 , A61L2300/62 , C09B61/00 , C09B67/0097 , C12N1/04 , C12N11/02 , C12N11/04 , C12P1/00
摘要： The present disclosure relates to capsules having a core and one or more capsular walls surrounding the core, wherein at least one of the capsular walls comprises a polymer comprising epsilon-poly-lysine or a derivative thereof.
摘要翻译： 本公开涉及具有芯和围绕芯的一个或多个荚膜壁的胶囊，其中至少一个荚膜壁包含包含ε-聚赖氨酸或其衍生物的聚合物。
-
公开(公告)号：US20110106000A1
公开(公告)日：2011-05-05
申请号：US13000527
申请日：2009-06-23
IPC分类号： A61M37/00 , A61K8/02 , A61K8/96 , A61K8/66 , A61K8/14 , A61K8/11 , A61K8/99 , A61Q19/08 , A61Q19/00
CPC分类号： A23B4/16 , A23B4/22 , A61K9/7007 , A61K9/703 , A61K33/00 , A61K35/747 , A61K38/44 , A61K38/465 , A61K45/06 , A61M35/00 , C12N11/00 , C12P3/00 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/478 , Y02A50/481
摘要： The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides compositions, methods and uses for skin cosmesis.
摘要翻译： 本公开提供一种具有壳体的装置，其具有阻挡表面和接触表面，并且壳体中的组合物具有一氧化氮前体和表达内源性酶的分离的酶或活细胞，用于将一氧化氮气体前体转化为一氧化氮 气体或在基板上具有产生导致一氧化氮气体前体转化为一氧化氮气体的催化剂的活性。 本公开还提供了皮肤美容的组合物，方法和用途。
-
3.发明授权Cell and enzyme compositions for modulating ale acids, cholesterol and triglycerides 有权用于调节酸，胆固醇和甘油三酸酯的细胞和酶组合物公开(公告)号：US08932578B2
公开(公告)日：2015-01-13
申请号：US12492629
申请日：2009-06-26
CPC分类号： C12N9/80 , A23L33/135 , A23V2002/00 , A61K9/0024 , A61K9/1652 , A61K9/5021 , A61K9/5031 , A61K9/5052 , A61K31/785 , A61K35/742 , A61K35/745 , A61K35/747 , A61K38/00 , A61K38/465 , A61K38/50 , C12N11/02 , C12Q1/34 , C12Y305/01024 , Y02A50/473 , A61K2300/00
摘要： The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a biologically active agent which decreases the amount of the target compound; b) a retainer for retaining the biologically active agent by contacting the agent to limit movement of the agent; and c) a carrier.
摘要翻译： 本发明涉及固定或包封的酶和/或细胞以降低胆汁酸和胆固醇。 本发明还涉及定量测定胆汁酸的方法。 本发明提供了用于减少动物胃肠道中的目标化合物的量的组合物，其包含：a）减少目标化合物的量的生物活性剂; b）用于通过使所述试剂接触以限制所述试剂的运动来保持所述生物活性剂的保持器; 和c）载体。
-
4.发明申请BACTERIAL COMPOSITIONS FOR PROPHYLAXIS AND TREATMENT OF DEGENERATIVE DISEASE 审中-公开用于预防和治疗退行性疾病的细菌组合物公开(公告)号：US20110217368A1
公开(公告)日：2011-09-08
申请号：US13111105
申请日：2011-05-19
摘要： The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 μmol glycodeoxycholic acid (GDCA)/gram/hour and >2 μmol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 μmol GDCA/g/hr and >7 μmol TDCA/g/hr when measured over 30 minutes.
摘要翻译： 本公开提供了用于降低血清胆固醇，血清脂质，体脂肪或致动脉粥样硬化指数或用于预防或治疗动脉粥样硬化，心血管或脑血管疾病的口服组合物，其包含高度bsh活性细菌，其分离物或上清液; 其中高度bsh活性细菌分别在1小时5小时内测量时分解>50μmol脱氧胆酸（GDCA）/克/小时和>2μmol牛磺脱氧胆酸（TDCA）/克/小时，或降解>65μmolGDCA / g / hr和>7μmolTDCA / g / hr。
-
5.发明授权Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides 有权用于调节胆汁酸，胆固醇和甘油三酸酯的细胞和酶组合物公开(公告)号：US07939061B2
公开(公告)日：2011-05-10
申请号：US10546990
申请日：2004-03-01
CPC分类号： C12N9/80 , A23L33/135 , A23V2002/00 , A61K9/0024 , A61K9/1652 , A61K9/5021 , A61K9/5031 , A61K9/5052 , A61K31/785 , A61K35/742 , A61K35/745 , A61K35/747 , A61K38/00 , A61K38/465 , A61K38/50 , C12N11/02 , C12Q1/34 , C12Y305/01024 , Y02A50/473 , A61K2300/00
摘要： The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a biologically active agent which decreases the amount of the target compound; b) a retainer for retaining the biologically active agent by contacting the agent to limit movement of the agent; and c) a carrier.
摘要翻译： 本发明涉及固定或包封的酶和/或细胞以降低胆汁酸和胆固醇。 本发明还涉及定量测定胆汁酸的方法。 本发明提供了用于减少动物胃肠道中的目标化合物的量的组合物，其包含：a）减少目标化合物的量的生物活性剂; b）用于通过使所述试剂接触以限制所述试剂的运动来保持所述生物活性剂的保持器; 和c）载体。
-
6.发明申请Cell And Enzyme Compositions For Modulating Bile Acids, Cholesterol and Triglycerides 有权用于调节胆汁酸，胆固醇和甘油三酸酯的细胞和酶组合物公开(公告)号：US20100074933A1
公开(公告)日：2010-03-25
申请号：US12492629
申请日：2009-06-26
CPC分类号： C12N9/80 , A23L33/135 , A23V2002/00 , A61K9/0024 , A61K9/1652 , A61K9/5021 , A61K9/5031 , A61K9/5052 , A61K31/785 , A61K35/742 , A61K35/745 , A61K35/747 , A61K38/00 , A61K38/465 , A61K38/50 , C12N11/02 , C12Q1/34 , C12Y305/01024 , Y02A50/473 , A61K2300/00
摘要： The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a biologically active agent which decreases the amount of the target compound; b) a retainer for retaining the biologically active agent by contacting the agent to limit movement of the agent; and c) a carrier.
摘要翻译： 本发明涉及固定或包封的酶和/或细胞以降低胆汁酸和胆固醇。 本发明还涉及定量测定胆汁酸的方法。 本发明提供了用于减少动物胃肠道中的目标化合物的量的组合物，其包含：a）减少目标化合物的量的生物活性剂; b）用于通过使所述试剂接触以限制所述试剂的运动来保持所述生物活性剂的保持器; 和c）载体。
-
公开(公告)号：US10660857B2
公开(公告)日：2020-05-26
申请号：US13111105
申请日：2011-05-19
IPC分类号： A61K35/747 , A61K35/744 , C12N1/20 , A61K9/16 , C12R1/225 , C12N11/10 , A61K9/50 , A23C9/123 , A23L33/135
摘要： The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 μmol glycodeoxycholic acid (GDCA)/gram/hour and >2 μmol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 μmol GDCA/g/hr and >7 μmol TDCA/g/hr when measured over 30 minutes.
-
8.发明申请Nitric Oxide Device and Method for Wound Healing, Treatment of Dermatological Disorders and Microbial Infections 审中-公开伤口愈合的一氧化氮装置和方法，皮肤病和微生物感染的治疗公开(公告)号：US20110104240A1
公开(公告)日：2011-05-05
申请号：US13000555
申请日：2009-06-23
IPC分类号： A61K9/70 , A61K9/127 , A61K9/14 , A61K9/16 , A61K35/00 , A61K38/43 , A61K38/44 , A61K38/45 , A61K38/46 , A61K38/48 , A61K35/74 , A61P31/00 , A61P17/00 , A61P17/02 , A61M37/00
CPC分类号： A23B4/16 , A23B4/22 , A61K9/7007 , A61K9/703 , A61K33/00 , A61K35/747 , A61K38/44 , A61K38/465 , A61K45/06 , A61M35/00 , C12N11/00 , C12P3/00 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/478 , Y02A50/481
摘要： The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides methods and uses for treating wounds, microbial infections and dermatological disorders and for preserving meat products.
摘要翻译： 本公开提供一种具有壳体的装置，其具有阻挡表面和接触表面，并且壳体中的组合物具有一氧化氮前体和表达内源性酶的分离的酶或活细胞，用于将一氧化氮气体前体转化为一氧化氮 气体或在基板上具有产生导致一氧化氮气体前体转化为一氧化氮气体的催化剂的活性。 本公开还提供了治疗伤口，微生物感染和皮肤病学障碍以及用于保存肉制品的方法和用途。
-
公开(公告)号：US20170296092A1
公开(公告)日：2017-10-19
申请号：US15514413
申请日：2015-09-25
申请人： Mitchell Lawrence JONES , Alain LABBE , Mark Sasha DRLIK , Christian Terry ROCH MCMECHAN , PROGENITY, INC.
CPC分类号： A61B5/065 , A61B1/041 , A61B5/0017 , A61B5/002 , A61B5/0086 , A61B5/073 , A61B5/6861 , A61B5/7264 , A61B2560/0443 , A61B2560/0462 , A61B2562/162 , H04B10/1143 , H04B13/00
摘要： Various embodiments are described herein for a device, system, and method for identifying a location of an ingestible device within a gastrointestinal tract of a body. In some embodiments, the ingestible device includes a sensing unit with an axial optical sensing sub-unit located proximal to at least one end of the device, and a radial optical sensing sub-unit located proximal to a radial wall of the device, and may autonomously identify a location within the gastrointestinal tract. In some embodiments, the ingestible device includes optical illumination sources and detectors that operate at a plurality of different wavelengths, and may discern regions of a gastrointestinal tract by using the reflection properties of organ tissue and occasional particulates. In some embodiments, the ingestible device may sample fluid or release medicament based on a detected device location.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.025 秒)